Document is current

Article History

Received: 8 August 2022

Accepted: 7 January 2023

First Online: 10 February 2023

Declarations

:

: Filipe Veloso Gomes has received research grants from Terumo; educational grants from Terumo, Medtronic, Guerbet; speaker honoraria from Bayer, Guerbet, Medtronic, Roche. Thierry-de-Baere has received consulting fees from Astra-Zeneca, Boston-Scientific, Guerbet, Medtronic and Terumo. Gontran Verset has received honoraria for lectures from Terumo, BTG, Bayer. Élia Coimbra—no conflicts of interest Gerardo Tovar-Felice has received a research grant from Terumo. Katerina Malagari has received honoraria for lectures from Merit Medical, BTG, Boston Scientific, Terumo. Jordi Bruix has received consulting fees from AbbVie, Adaptimmune, Arqule, Astra-Medimmune, Basilea, Bayer-Shering Pharma, Bio-Alliance, BMS, BTG- Biocompatibles, Eisai, Gilead, Incyte, Ipsen, Kowa, Lilly, MSD, Nerviano, Novartis, Polaris, Quirem, Roche, Sirtex, Sanofi, Terumo; honararia for lectures from Bayer, Eisai, BTG/Boston Scientific, Sirtex, Terumo, Ipsen, Astra-Zeneca.

: Lisbon, Portugal: Ethics Committee Nova medical School/Faculdade de Cieências Médicas 36/2017/CEFCM Veloso Gomes, F.; Oliveira, J.A.; Tomé Correia, M.; Vasco Costa, N.; Abrantes, J.; Torres, D.; Pereira, P.; Ferreira, A.I.; Luz, J.H.; Spaepen, E.; Bilhim, T.; Coimbra E. Chemoembolization of Hepatocellular Carcinoma with Drug-Eluting Polyethylene Glycol Embolic Agents: Single-Center Retrospective Analysis in 302 Patients. <i>J Vasc Interv Radiol </i>2018, <i>29</i>, 841-849. . Paris, France: Ethics Committee Erasmus University Hospitals ULB / Comité d’Ethique hospitalo-facultaire Erasme ULB (Brussels) – P2017/233 Ethics Committee University Hospitals St. Luc UCL / Comité d’Ethique hospitalo-facultaire Saint-Luc UCL (Brussels) – T127E2 de Baere, T.; Guiu, B.; Ronot, M.; Chevallier, P.; Sergent, G.; Tancredi, I.; Tselikas, L.; Dioguardi Burgio, M.; Raynaud, L.; Deschamps, F.; Verset, G. Real Life Prospective Evaluation of New Drug-Eluting Platform for Chemoembolization of Patients with Hepatocellular Carcinoma: PARIS Registry. <i>Cancers (Basel) </i>2020, 12, 3405. . Athens, Greece: PK Doxorubicin study: Cantonal Committee of Ethics of Research on Human Being (Lausanne) – 460/15 Hellenic Republic Ministry of Health National Ethics Committee (Athens) – 115/15 South-Mediterranean II Ethics Committee / Comité de Protection des Personnes Sud-Méditerranée II (Marseille) – 215 R15 Ethics Committee for Clinical Investigation Barcelona University Hospitals (Barcelona) – HCB/2015/0689 Malagari et al. Polyethylene-glycol drug-eluting embolic microspheres loaded with doxorubicin for the treatment of hepatocellular carcinoma: feasibility, safety and pharmacokinetic study. <i>JVIR </i>2021, <i>provisionally accepted </i>Badalona, Spain – IRB exemption as per local policy: Tovar-Felice, G.; Garcia-Gamez, A.; Benito-Santamaria, V.; Balaguer-Paniagua, D.; Villalba-Auñon, J.; Sampere-Moragues, J. Unresectable hepatocellular carcinoma treatment with doxorubicin-eluting polyethylene glycol microspheres: a single-center experience. <i>Hepat Oncol</i>. 2021, <i>8</i>, HEP38. Brussels., Belgium - IRB exemption as per local policy: Retrospective single-center study of 105 patients – Retrospective registry from Dr. Gontran Verset. - Not yet published.